• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Cannabis Science Acquires 74.9% of a German Bio-Med Company

April 5, 2017

 

 

IRVINE, CA--(Marketwired - Apr 5, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in cannabis formulation-based drug development, is pleased to announce its subsidiary Cannabis Science Europe GmbH (CBIS EU) has acquired 74.9% of a German Bio Med Corporation "Jinvator Bio Med GmbH" (Jinvator), the creator of an ultra-sensitive rapid HIV/AIDS test based on nano-particle technology for the detection of HIV in the early stage of infection.

 

CBIS EU and Jinvator have agreed to immediately refine, develop, and bring the nanoGold test to market -- a product that expedites early HIV-testing without the risk of diagnostic gaps. Both Companies will mutually share the development of intellectual property and innovative advancements of bringing the technology to consumers now.

 

HIV/AIDS is one of the most severe epidemics of modern times, affecting 34 million patients globally. The prospect of being cured increases with early detection. Recent studies have shown that newborns, when timely diagnosed, can be cured from HIV/AIDS. Despite current tests being able to detect HIV within three months of infection with a 99% chance, the 1% uncertainty factor still remains. The nanoGold test aims to eliminate that risk by using nanotechnology to safely diagnose HIV within one week of infection. The highly-sensitive nanoGold test has the capability to detect a single virus in blood or saliva with a 10,000-fold dilution. The test is also suitable for diagnosing HIV in newborn babies.

 

"There is an enormous market for the nanoGold test, ranging from the general public, to diagnostic laboratories, blood banks, and hospitals. As an original and unrivaled testing kit designed for convenience and quick diagnosis, there is opportunity for the product to be well-received globally. In addition, the nanoGold test is produced to be more cost-effective for the consumer, in contrast to other related products on the market. Moreover, it can be performed and evaluated easily without technical aids," stated Jinvator President, Dr. R. S. Bhardwaj.

 

About Jinvator Bio Med GmbH

 

Jinvator Bio Med GmbH is a German Bio Medical Corporation that focuses on the production of pharmaceutical raw materials, development of therapeutics, medication, diagnostics and related products. The company assumes commercial and technological consulting and services for the biotechnological sector.

 

About Cannabis Science, Inc.

 

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Read more articles tagged:

Please reload

LATEST NEWS
Please reload

Please reload

DMO

© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.